Compare Johnson & Johnson (JNJ) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs iShares MSCI China ETF — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while iShares MSCI China ETF trades at $52.55 (market cap $5.94B). The key difference: Johnson & Johnson is far larger — about 104.1× iShares MSCI China ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and iShares MSCI China ETF for 63 Days on average.
| JNJ | MCHI | |
|---|---|---|
Market Cap | $618.09B | $5.94B |
Volume | 6,050,983 | 1,575,471 |
Sector | Health | Broad Market / Factor |
52-Week High | $278.43 | $65.59 |
52-Week Low | $186.00 | $50.48 |
Typical Hold Time | 129 Days | 63 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
MCHI trades at $51.36, down 0.54% with bearish technical signals from moving averages. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights trade tensions ahead of U.S.-China talks, though corporate profits surged 26% in Q2. Technical indicators show oversold conditions with RSI at 25.44 suggesting potential for near-term bounce.
The outlook remains cautious given China's macroeconomic pressures and trade uncertainties. Investment opportunity exists in MCHI's significant discount to historical valuations versus U.S. indices. Key risks include potential export controls, protectionism threats, and China's reliance on infrastructure spending rather than broad stimulus to support growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
